(Q37937880)

25 August 2017

1 reference

title

Small cell lung cancer: new clinical recommendations and current status of biomarker assessment (English)

1 reference

25 August 2017

0 references

1 reference

David Planchard

1

1 reference

25 August 2017

Cécile Le Péchoux

series ordinal

2

1 reference

25 August 2017

language of work or name

1 reference

1 September 2011

1 reference

European Journal of Cancer

25 August 2017

published in

1 reference

25 August 2017

volume

47 Suppl 3

1 reference

25 August 2017

page(s)

S272-83

1 reference

Global cancer statistics, 2002

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 9

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology G

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

Prophylactic cranial irradiation in extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970173-3

7 January 2021

10.1016/S0959-8049(11)70173-3

Identifiers

DOI

1 reference

25 August 2017

1 reference